Contract services that help cell and gene therapy companies run trials, make treatments, and move patients and samples through approval and delivery.
Accelerated cell & gene therapy services (trials, manufacturing, matching)
Recent breakthroughs — China now leading next‑gen CAR‑T trials, CRISPR advances and a successful personalized gene therapy case, plus organ preservation and transplant biology that extend transport windows — are creating urgent demand for manufacturing, trial, delivery and logistics services that can lower time and cost across custom genetic treatments.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ☆☆☆☆☆ (0/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Sep 28, 2026 Nature: China now leads the world in trials for next-gen CAR-T therapies
- Sep 28, 2026 Forbes (contributor net): What’s The Latest On CRISPR Gene Editing Technology?
- Sep 28, 2026 Nature: Old hearts age backwards: transplanted organs adjust to host's biological age
- Sep 28, 2026 Peter Attia: #409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringin
- Jul 25, 2026 MIT Technology Review: The quest to keep organs alive outside the body
- Jul 24, 2026 Nature: Personalized gene therapy relieves severe epilepsy in two boys
- Jul 24, 2026 MIT Technology Review: The Download: an organ transplant breakthrough, and homegrown Chinese chips
